The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I, dose-escalation, multicenter study of ACT-PFK-158, 2HCl in patients with advanced solid malignancies explores a first-in-human inhibitor of glycolysis.
 
Rebecca Ann Redman
Research Funding - Advanced Cancer Therapeutics (Inst)
 
Paula Raffin Pohlmann
No Relationships to Disclose
 
Michael R. Kurman
Consulting or Advisory Role - Advanced Cancer Therapeutics
 
Gilles Tapolsky
Employment - Advanced Cancer Therapeutics
Leadership - Advanced Cancer Therapeutics
Stock and Other Ownership Interests - Advanced Cancer Therapeutics
Patents, Royalties, Other Intellectual Property - Advanced Cancer Therapeutics
Travel, Accommodations, Expenses - Advanced Cancer Therapeutics
 
Jason Chesney
No Relationships to Disclose